Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.
Use of nonsystemic antimicrobials with activity against enteropathogens is a promising approach for treatment of infectious diarrhea and other nonsystemic gastrointestinal infections. Rifaximin is approved by the US FDA for the treatment of travelers' diarrhea caused by noninvasive strains of Escherichia coli in patients aged 12 years and older, and for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients aged 18 years or older. Rifaximin has been available in Italy since 1987 and overall is approved in 33 countries for various conditions, such as acute and chronic infections, bacterial diarrhea, HE, and pre- and postsurgical prophylaxis. There is accumulating evidence on the benefit of rifaximin for nonsystemic gastrointestinal infections. This article will serve as an update on rifaximin. The pharmacology and pharmacodynamics of rifaximin along with an updated review on the bacterial susceptibility to rifaximin will be presented. Finally, clinical trials with rifaximin for nonsystemic gastrointestinal indications will be updated.
Cottreau
Jessica
J
University of Houston College of Pharmacy, 1441 Moursund Street, Houston, TX 77030, USA.
Baker
Shannon F
SF
DuPont
Herbert L
HL
Garey
Kevin W
KW
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003967:Diarrhea / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D005767:Gastrointestinal Diseases / Q000188:drug therapy* / Q000382:microbiology*; D006501:Hepatic Encephalopathy / Q000517:prevention & control; D006801:Humans; D008826:Microbial Sensitivity Tests; D012294:Rifamycins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014195:Travel
D000900:Anti-Bacterial Agents; D012294:Rifamycins